

## SUBB2M PAPER PUBLISHED IN BMC CANCER JOURNAL

- Paper by researchers at the Institute for Glycomics, Griffith University and University of Adelaide exploring use of INOVIQ's SubB2M technology in breast cancer published in BMC Cancer journal
- SubB2M was used to show that Neu5Gc serum biomarker levels can discriminate breast cancer patients from cancer-free individuals with 99% sensitivity and 100% specificity, in the samples tested
- Researchers conclude "Neu5Gc serum biomarkers are a promising new tool for disease monitoring for breast cancer that may complement current imaging- and biopsy-based approaches
- Peer reviewed publication adds to growing body of evidence on SubB2M and provides further international exposure for INOVIQ's SubB2M technology with research and clinical community

**Melbourne, Australia, 6 April 2022:** INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that a paper using the technology underpinning the Company's SubB2M test has now moved from preprint to full publication in international peer reviewed journal, *BMC Cancer*.

In the paper, entitled, "*N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease*", researchers from Griffith University's Institute for Glycomics and the University of Adelaide discussed the full data, methods and results underlying the previously announced (15 February 2021) poster presentation showing that SubB2M can be used to distinguish all stages of breast cancer (n=96) from cancer-free control (n=22) blood samples with over 95% sensitivity and 100% specificity, in the samples tested.

In this paper, researchers used an optimized SubB2M surface plasmon resonance (SPR)-based assay to analyse sera from breast cancer patients for their Neu5Gc levels. Neu5Gc is a cancer biomarker that is found at elevated levels in human tumour tissues, cells, and secretions.

It showed that the SubB2M SPR-assay was able to discriminate common (invasive ductal carcinoma and invasive lobular carcinoma) as well as rare forms (mucinous carcinoma) of breast cancer, from cancer-free controls, supporting its utility across multiple breast cancer subtypes and the potential for widespread commercial viability. This SubB2M study was funded by a grant from the US Department of Defense (W81XWH-20-1-0527) that was awarded to the Institute for Glycomics, Griffith University.

The paper concludes, "*Biomarkers that can accurately and specifically monitor response to treatment and disease progression would ... drastically improve patient outcomes. Our SubB2M lectin assay offers the opportunity to exploit measurement of Neu5Gc biomarkers as a path to achieve these outcomes.*"

Griffith University's Professor Mike Jennings said, "*We are very excited about the publication of this paper, which demonstrates elevated levels of this sugar biomarker at all stages of breast cancer. This biosensor-based assay has the potential to detect and monitor breast cancer. Further work on the identity of the breast cancer-specific Neu5Gc biomarkers will form the basis of tests on other technology platforms.*"

Dr Leearne Hinch, INOVIQ's CEO commented, "*This paper highlights the potential for our SubB2M technology to be a promising new way of monitoring and detecting breast cancer in complement to other current methods. Recognition in peer reviewed publications like BMC Cancer provides further validation of this work and is an important part of our strategy for building international awareness of INOVIQ's SubB2M and other technologies with researchers and clinicians. Congratulations to all the collaborators involved in this significant body of work.*"

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research. It has an impact factor of 4.4. The paper is available online at <https://rdcu.be/cJ21m>.

INOVIQ initially plans to develop and commercialise SubB2M-based blood tests for monitoring recurrence in patients already diagnosed with breast and ovarian cancers. The Company then plans to undertake further studies to expand applications for use of the SubB2M tests to other uses and cancers.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

## COMPANY CONTACTS

**Dr Leearne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

## FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.